Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects

Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016

(2018) Christopher M. Jones et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice

(2018) Jia Zhan et al.   NEUROPHARMACOLOGY

The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats

(2017) Zhi-Bing You et al.   NEUROPHARMACOLOGY

Existing and Future Drugs for the Treatment of the Dark Side of Addiction

(2016) George F. Koob et al.   Annual Review of Pharmacology and Toxicology

The dopamine D3 receptor, a quarter century later

(2016) Pierre Sokoloff et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment

(2016) Vivek Kumar et al.   JOURNAL OF MEDICINAL CHEMISTRY

Relationship between Nonmedical Prescription-Opioid Use and Heroin Use

(2016) Wilson M. Compton et al.   NEW ENGLAND JOURNAL OF MEDICINE

The selective dopamine D3 receptor antagonist, SR 21502, reduces cue-induced reinstatement of heroin seeking and heroin conditioned place preference in rats

(2015) Ewa Galaj et al.   DRUG AND ALCOHOL DEPENDENCE

High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice

(2015) Comfort A. Boateng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis

(2015) Thomas M. Keck et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nonmedical Prescription Opioid Use in Childhood and Early Adolescence Predicts Transitions to Heroin Use in Young Adulthood: A National Study

(2015) Magdalena Cerdá et al.   JOURNAL OF PEDIATRICS

Understanding opioid reward

(2015) Howard L. Fields et al.   TRENDS IN NEUROSCIENCES

Prescription Opioid Abuse: A Literature Review of the Clinical and Economic Burden in the United States

(2014) Roxanne Meyer et al.   Population Health Management

Opioid Withdrawal Syndrome: Emerging Concepts and Novel Therapeutic Targets

(2013) Ashish K. Rehni et al.   CNS & Neurological Disorders-Drug Targets

Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice

(2013) Rui Song et al.   NEUROPHARMACOLOGY

Morphine-induced trafficking of a mu-opioid receptor interacting protein in rat locus coeruleus neurons

(2013) Kellie M. Jaremko et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice

(2011) Rui Song et al.   ADDICTION BIOLOGY

Dopamine D3 receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats

(2011) Amanda E. Higley et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The acute administration of the selective dopamine D3 receptor antagonist SB-277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats

(2011) Onarae V. Rice et al.   SYNAPSE

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

(2010) Christian A. Heidbreder et al.   Annals of the New York Academy of Sciences

Delay of Ejaculation Induced by SB-277011, a Selective Dopamine D3 Receptor Antagonist, in the Rat

(2009) Pierre Clément et al.   Journal of Sexual Medicine

Contribution of dopamine receptors to periaqueductal gray-mediated antinociception

(2009) Paul J. Meyer et al.   PSYCHOPHARMACOLOGY